Canaan Partners to invest $50-80m in Israel

The venture capital firm has closed its $600 million ninth fund.

Canaan Partners plans to invest $50-80 million in Israeli start-ups from its new $600 million fund, Canaan IX, Canaan Partners general partner Izhar Shay told "Globes". The new fund brings total capital under management by Canaan to $3.5 billion. The firm operates in the US, India, and Israel.

Canaan Partners, founded in 1987, plans to invest the new fund in building disruptive global companies in the technology and healthcare sectors. Its Israeli portfolio includes touch screen developer N-trig Ltd., online live video developer LiveU Ltd., and 3D gesture recognition software developer PrimeSense Ltd.

Canaan Partners originally planned to raise $500 million for its ninth fund, but received strong demand from its existing limited partner base, as well as selected new limited partners.

The firm has been operating in Israel for over a decade and in 2005, it opened a local office run by Shay, whose entrepreneurial track record includes V-Secure Technologies, sold to Radware Ltd. (Nasdaq: RDWR) in 2005, and Business Layers, sold to Netegrity Inc. (Nasdaq: NETE) in 2003.

Published by Globes [online], Israel business news - www.globes-online.com - on January 10, 2012

© Copyright of Globes Publisher Itonut (1983) Ltd. 2012

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Yaron Daniely Replacing Ritalin

Alcobra has had two successful Nasdaq offerings this year as it develops an ADHD treatment with fewer side effects.

Twitter Facebook Linkedin RSS Newsletters